Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Illuminate your research with Jackson ImmunoResearch

Products are for professional/laboratory use only.

Highly Cross-Adsorbed Secondary Antibodies for Immunofluorescence Staining

Immunofluorescence (IF) is an immunochemical technique that enables the detection and localization of antigens on tissue or cells using microscopy or flow cytometry.  Fluorescent immunostaining allows protein expression patterns and interactions to be characterized. Advances in equipment mean new techniques can use IF to increase the detail, resolution, and complexity of the results that can be achieved. 

Jackson ImmunoResearch offers a wide range of Secondary Antibodies suitable for IF, available as fluorescent conjugates that cover the most commonly used excitation sources and filter sets from blue to infrared emissions, including Alexa Fluor®, Brilliant Violet™, Cyanine dyes, and fluorescent proteins. Our short article introduces immunostaining and what considerations are important for optimal experimental setup.

Learn more about:

  • The principles of Immunostaining
  • Primary antibody considerations
  • Selecting the optimal secondary antibody
  • Labeling multiple targets
  • Blocking and controls

Illuminate your research

Click Here >



Request a Quote

Request Quote

Recent Posts

Roche – New KAPA NGS Reagents

Roche KAPA kits offer a range of high-performance products for molecular biology applications in next-generation sequencing (NGS). KAPA RNA EvoPrep Kit The KAPA RNA EvoPrep…

Read full article

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article